SCHEMBL4533528

SCHEMBL4533528

Cc1c(Br)ccc(S(=O)(=O)N2CCC3(CC2)CN(C2CC2)C(=O)CO3)c1C

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FASN P49327 5/20 0.50
ALDH1A1 P00352 6/20 0.35
NPSR1 Q6W5P4 1/20 0.34
TSHR P16473 2/20 0.34
MAPK1 P28482 2/20 0.34
HTT P42858 2/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SIGMAR1 Q99720 2/20 0.32
MCOLN3 Q8TDD5 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
OPRM1 P35372 1/20 0.31
KCNH2 Q12809 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4542291 0.84 FASN (0.51) FASNALDH1A1LMNAKMT2ASMN1; SMN2
SCHEMBL4536273 0.84 FASN (0.57) FASNALDH1A1TSHRMAPK1LMNA
SCHEMBL4540336 0.83 FASN (0.48) FASNALDH1A1TSHRMAPK1HTT
SCHEMBL4542521 0.81 FASN (0.52) FASNTSHRMAPK1HTTLMNA
SCHEMBL4536313 0.81 FASN (0.63) FASNALDH1A1TSHRMAPK1HTT
SCHEMBL4534373 0.80 FASN (0.51) FASNALDH1A1MAPK1LMNAMEN1
SCHEMBL4536297 0.80 FASN (0.58) FASNALDH1A1TSHRMAPK1HTT
SCHEMBL4537666 0.80 FASN (0.49) FASNALDH1A1TSHRHTTLMNA
SCHEMBL4539996 0.80 FASN (0.57) FASNALDH1A1TSHRMAPK1MEN1
SCHEMBL4533515 0.79 FASN (0.55) FASNALDH1A1TSHRMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2637660-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2013-09-18 EP disclosed
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC 2013-09-12 US disclosed
WO-2012064642-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 FASN 1/4885ALDH1A1 199/4885NPSR1 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.